Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE (palbociclib) and talazoparib in Combination with CB-839
pharmaceutical investing Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights
Blue Sky Uranium Acquires Key Subsurface Data for Corcovo Uranium Project, Mendoza Province, Argentina
Group Eleven Drills Best Hole Yet at Ballywire: 39.7m of 9.5% Zn+Pb, 131 g/t Ag and 0.27% Cu, incl. 5.6m of 16.6% Zn+Pb, 370 g/t Ag and 0.86% Cu
